Phase 1 Pilot: 225Ac-PSMA-617 alpha-emitter targeting PSMA in prostate cancer

This single-center pilot study compares 177Lu-PSMA-617 and 225Ac-PSMA-617 radioligand therapies administered via IV or intra-arterial routes in patients with localized high-risk prostate cancer scheduled for prostatectomy. Researchers at Thomas Hope conduct biospecimen collection and imaging assessments to evaluate beta (177Lu) versus alpha (225Ac) mechanisms, aiming to inform future comparative safety and effectiveness over long-term follow-up.